GlaxoSmithKline is paying $321.4 million to buy a closely held Swiss company whose technology it hopes will speed up the development of vaccines in hotly pursued areas including hepatitis C, HIV and malaria.
You are receiving this email because you subscribed to this feed at blogtrottr.com.